Приказ основних података о документу
In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
dc.creator | Shi, Changzhi | |
dc.creator | Ignjatović, Jelisaveta | |
dc.creator | Liu, Tingting | |
dc.creator | Han, Meihua | |
dc.creator | Cun, Dongmei | |
dc.creator | Đuriš, Jelena | |
dc.creator | Yang, Mingshi | |
dc.creator | Cvijić, Sandra | |
dc.date.accessioned | 2021-06-01T08:45:24Z | |
dc.date.available | 2021-06-01T08:45:24Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1818-0876 | |
dc.identifier.uri | https://farfar.pharmacy.bg.ac.rs/handle/123456789/3902 | |
dc.description.abstract | This study aims to understand the absorption patterns of three different kinds of inhaled formulations via in silico modeling using budesonide (BUD) as a model drug. The formulations investigated in this study are: (i) commercially available micronized BUD mixed with lactose (BUD-PT), (ii) BUD nanocrystal suspension (BUD-NC), (iii) BUD nanocrystals embedded hyaluronic acid microparticles (BUD-NEM). The deposition patterns of the three inhaled formulations in the rats’ lungs were determined in vivo and in silico predicted, which were used as inputs in GastroPlus™ software to predict drug absorption following aerosolization of the tested formulations. BUD pharmacokinetics, estimated based on intravenous data in rats, was used to establish a drug-specific in silico absorption model. The BUD-specific in silico model revealed that drug pulmonary solubility and absorption rate constant were the key factors affecting pulmonary absorption of BUD-NC and BUD-NEM, respectively. In the case of BUD-PT, the in silico model revealed significant gastrointestinal absorption of BUD, which could be overlooked by traditional in vivo experimental observation. This study demonstrated that in vitro-in vivo-in silico approach was able to identify the key factors that influence the absorption of different inhaled formulations, which may facilitate the development of orally inhaled formulations with different drug release/absorption rates. | |
dc.publisher | Elsevier B.V. | |
dc.relation | info:eu-repo/grantAgreement/MESTD/inst-2020/200161/RS// | |
dc.relation | National Natural Science Foundation of China (Nos.81302720 and No.81573380) | |
dc.relation | European Cooperation in Science and Technology | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.source | Asian Journal of Pharmaceutical Sciences | |
dc.subject | Budesonide | |
dc.subject | In silico physiologically-based pharmacokinetic modeling | |
dc.subject | Nanocrystal suspension | |
dc.subject | Nanocrystal-embedded microparticles | |
dc.subject | Pulmonary drug delivery | |
dc.title | In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug | |
dc.type | article | |
dc.rights.license | BY-NC-ND | |
dcterms.abstract | Схи, Цхангзхи; Игњатовић, Јелисавета; Ђуриш, Јелена; Цвијић, Сандра; Лиу, Тингтинг; Хан, Меихуа; Цун, Донгмеи; Yанг, Мингсхи; | |
dc.citation.volume | 16 | |
dc.citation.issue | 3 | |
dc.citation.spage | 350 | |
dc.citation.epage | 362 | |
dc.citation.rank | aM21 | |
dc.identifier.wos | 000669676300008 | |
dc.identifier.doi | 10.1016/j.ajps.2020.12.001 | |
dc.identifier.scopus | 2-s2.0-85102878238 | |
dc.identifier.fulltext | https://farfar.pharmacy.bg.ac.rs/bitstream/id/9041/In_vitro-in_vivo_pub_2021.pdf | |
dc.type.version | publishedVersion |